China COPD & Asthma Market 2022-2028

China COPD & Asthma Market 2022-2028

China COPD & Asthma Market Size, Share & Trends Analysis Report By Disease Type (Asthma and COPD), by Treatment (Drugs, Surgery and Oxygen therapy), and By End-User (Hospitals, Homecare setting and Clinics Center) Forecast Period (2021-2028)

The China Chronic obstructive pulmonary disease (COPD) & asthma market was valued at around $3.5 billion in 2021 and is estimated to reach nearly $4.7 billion in 2028, growing at a CAGR of 6.9% during the forecast period (2021-2028). The major factors that are contributing to the growth of asthma & COPD market in China, include, the rising prevalence of respiratory diseases, such as COPD, asthma, and emphysema backed by the excessive consumption of tobacco and alcohol. The excessive smoking is responsible for the increasing respiratory diseases, such as COPD and asthma in the country, which in turn is increasing the demand for COPD and asthma treatment. According to the American Thoracic Society, China is the world's largest manufacturer and consumer of tobacco products. In 2021, there were more than 320 million smokers in China, representing 67.0% of the total adult male and 4.0% of the adult female populations in that country. From June 2015 to May 2021, a survey was conducted by the Ministry of Health and Ministry of Science and Technology of China. About 51,000 citizens participated in the survey with 21,500 men and 29,500 women. The study concludes that 100 million adults in 2017 had the problem of COPD in the country. The prevalence is higher in men as compared to women. As per an estimate, there were 68.4 million men and 31.5 million women who were affected by COPD. COPD is characterized by the persistent respiratory symptoms, and airflow limitation due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases. In 2021, as per the Global Burden of Disease Study, it is the fifth leading cause of mortality in China. It is a universally prevalent disease that is treatable and preventable, the country has a COPD prevalence rate of 5% to 13%, with an 8.2% rate among people aged above 40 years. Moreover, the presence of top pharmaceutical manufacturers focusing on the development of the advanced, portable inhalation devices is projected to contribute to the market during the forecast period.

The prevalence of Asthma in the country is not as high as compared to COPD, however, it is growing constantly. In 2021, as per the Global Asthma Report, in Beijing, the total prevalence of asthma in children aged less than 14 years in rural areas (1.3%) was much lower than in urban areas (3.7%), similarly, the diagnosis of asthma in those with symptoms (49% versus 74%). Compared to the urban asthmatic children (57%), only 36% of the rural asthmatic children received ICS. Results of a recent follow-up in urban Beijing found only 19% of children with asthma, had symptoms of asthma in the past 12 months after 6 years. Asthma diagnosis and treatment have improved across China. The promotion of GINA (Global Initiative for Asthma) guidelines in China, the formation of the National Cooperation Group of Children's Asthma, the use of asthma action plans, the availability of lung function and peak flow meters in many children's hospitals, and new portable electronic spirometers are all contributing factors to the growth of China asthma & COPD market.

Segmental Analysis

The report on China's Asthma and COPD market covers segments including disease type, treatment type, and end-user. Based on the disease type, the market is sub-segmented into asthma and COPD. The COPD segment is projected to exhibit substantial growth over the forecast period. The market for COPD was valued at around $2.3 billion in 2021 and it is anticipated to reach a valuation of nearly $3.1 billion by 2028, registering the highest CAGR of 7.2% over the forecast period. The COPD drugs have generated the highest market such as Symbicort, Spiriva, Ellipta, Daliresp/Daxas, Bevespi, Breztri, and Other. Ellipta products by GlaxoSmithKline PLC are widely prescribed for COPD, whereas, Advair, Flixotide/ Flovent by GlaxoSmithKline PLC is widely prescribed for Asthma. The asthma market was valued at nearly $1.2 billion in 2021 and is projected to reach around $1.6 billion in 2028, growing at a CAGR of 6.5% during the forecast period.

Based on treatment type, the market is segmented into drugs, surgery, and oxygen therapy. The drugs segment was valued at around $2.9 billion in 2021 and it is anticipated to reach a valuation of around $3.6 billion by 2028, growing at a CAGR of 6.2% over the forecast period. The technological advancement in respiratory drugs, and cost reductions are some of the major factors that are assisting the growth of asthma and COPD drugs. The surgery market includes Lung Volume Reduction Surgery (LVRS), Lung Transplant, and Bullectomy. Lung transplant for COPD and Asthma can help some people manage their symptoms. For severe asthma, doctors rarely recommend a lung transplant. A lung transplant can cure COPD and asthma. The market for lung transplants was valued at $5 million which is anticipated to reach $10 million in 2028. The number of lung transplantation procedures is comparatively lower than LVRS and Bullectomy in China, however, the high cost of lung transplant procedures has contributed to the highest market value. Oxygen therapy includes an oxygen concentrator, oxygen cylinder, and delivery devices. The market for oxygen therapy in China was around $589 million in 2021 which is estimated to reach around $1.1 billion in 2028, growing at a CAGR of 9.6% during the forecast period.

Further, based on end-user, the market is segmented into hospitals, homecare settings, and & clinics centers. The hospital segment held the highest market value of around $1.6 billion in 2021 and is estimated to reach around $2.2 billion in 2028, growing at a CAGR of 6.7% during the forecast period. A high percentage of the COPD and asthma population preferred to choose hospitals as the first line of treatment in the country. The availability of healthcare insurance is also promoting the hospital segment in the country. Further, the homecare setting segment is projected to grow at the highest CAGR of 7.8% during the forecast period. The availability of the advanced and portable inhalation devices is contributing to the homecare setting segment growth. The market for home care settings was valued at $791 million in 2021 and is estimated to reach around $1.1 billion in 2028.

Market Players Outlook

The key players in the asthma and COPD drug market are contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include AstraZeneca PLC, Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Grifols, S.A., Novartis AG, Merck Co., Inc., Pfizer Inc., and others. The strong presence of these leading market players in the country is benefitting the market. Extensive R&D and respiratory products under pipeline are creating enormous opportunities for the market in near future. For instance, pipeline product by GlaxoSmithKline that include SB240563 mepolizumab Nucala (Nasal polyposis) under-representation phase, GSK3511294 † (Asthma) and SB240563 mepolizumab Nucala (COPD) under Phase 3, and GSK3923868 (viral COPD exacerbations) under Phase 3.